You are here: Industry Insights > ADMA Biologics

News List

ADMA Biologics Launches COVID-19 ImmunoRank™ Neutralization MICRO-ELISA Assay americanpharmaceuticalreview
September 04, 2020
ADMA Biologics announced the launch of COVID-19 ImmunoRank Neutralization MICRO-ELISA, a proprietary, fully-validated ELISA assay for the detection of SARS-CoV-2 neutralizing antibodies in plasma.
Adma Biologics Launches COVID-19 Assay contractpharma
September 04, 2020
Adma Biologics Inc., an end-to-end commercial biopharmaceutical company, has launched COVID-19 ImmunoRank Neutralization MICRO-ELISA, a proprietary, fully-validated ELISA assay for the detection of SARS-CoV-2 neutralizing antibodies in plasma.
ADMA Biologics Opens New ADMA BioCenters Plasma Collection Facility americanpharmaceuticalreview
July 16, 2020
ADMA Biologics announced the commencement of operations and initiation of collections at its newest ADMA BioCenters plasma collection facility located in Knoxville, TN.
ADMA Biologics Opens New Plasma Collection Facility contractpharma
July 07, 2020
Aims to open 5 to 10 more collection centers by the end of 2022.
ADMA Biologics' shares surge after intravenous immune globulin drug product Asceniv gains FDA approval firstwordpharma
April 02, 2019
According to ADMA, the product's label will include a boxed warning about potential thrombosis and renal dysfunction or failure.
ADMA Biologics Reports FDA Compliance Status Update americanpharmaceuticalreview
September 06, 2018
ADMA Biologics announces that the U.S. Food and Drug Administration (FDA) inspection database classification website has been updated and confirms ADMA’s compliance status has improved to Voluntary Action Indicated (VAI).